Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMEA Efforts To Be Innovation-Friendly Include Shorter Review Times

Executive Summary

The European Medicines Agency expects its push to promote innovation will lead to increases in marketing authorization applications in the coming years

You may also be interested in...

European Risk Management Guidelines Could Expedite Product Approval

The European Medicines Agency's new risk management guideline could help to shorten the drug delivery process, agency Executive Director Thomas Lonngren said during the Drug Information Association's EuroMeeting March 7 in Paris

EU Biosimilar Guidance Offers Window To Bypass Comparative Trials

Manufacturers seeking regulatory approval of a follow-on biologic in the EU may be able to forgo clinical comparability trials under certain conditions, according to final guidelines on similar biologics issued by the European Medicines Agency March 8

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts